Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

Executive Summary

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.

You may also be interested in...



Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine

Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.

How Merck KgaA’s Life Science Unit Is Riding The Crest Of The Gene Therapy Wave

Udit Batra, member of Merck KGaA's executive board and CEO, life science, tells Scrip in an interview how the company is building on its play in the hot gene therapy area. Batra also outlines how the life science unit’s industry leading e-commerce platform already has the performance "of the level of Amazon or Alibaba" for the scientific space.

WTO Chief: Pharma Needs To 'Lift The Veil Of Opaqueness' In COVID-19 Vaccine Contracts

WTO director general says pharma could have done more on voluntary licensing for COVID-19 vaccines and also calls for better transparency of pricing and contracts to ensure “a level playing field” when it comes to saving lives.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel